A tumour infiltrating lymphocyte (TIL) therapy, lifileucel is designed to treat patients with advanced (unresectable or metastatic) melanoma who advanced on or after prior anti-PD-1/L1 therapy and targeted therapy.
Under the deal terms, Macomics will be responsible for identifying and characterising the antibody candidates against a new target leveraging its Enigmac macrophage drug discovery platform. Ono Pharmaceutical
Dewpoint’s discovery platform related to biomolecular condensates will be used to identify the drug candidates. The collaboration will enable combination of Novo Nordisk’s expertise in treating diabetes and
PBP1510 will mainly act on a tumour-specific protein called pancreatic adenocarcinoma upregulated factor (PAUF), which is overexpressed in most pancreatic cancer patients. PAUF overexpression is said to advance
Earlier, ARO-APOC3 received Orphan Drug designation from the FDA and the European Union. ARO-APOC3 is the firm’s investigational RNAi therapeutic targeting apolipoprotein C-III (APOC3). It is being developed
The oral androgen receptor inhibitor (ARi) darolutamide already received approval in China to treat non-metastatic castration-resistant prostate cancer (nmCRPC) patients at high risk of developing metastatic disease. The
With this approval, the firm intends to introduce Xerava in the Chinese market in the third quarter of this year. Xerava is a new fully synthetic, broad-spectrum, fluorocycline
The Series A round was co-led by Novartis Venture Fund and Sofinnova Partners and has seen participation from Pfizer Ventures, Mission BioCapital, Gimv, Pureos, Bristol Myers Squibb, Eli
If given approval, Nucala will become the first targeted anti-Interleukin-5 (IL-5) treatment in the country for adult and adolescent patients with SEA. A first-in-class monoclonal antibody to target
This funding round was primarily subscribed by current shareholders exercising their rights of first refusal. Leveraging this fund raise, Evergreen is launching a new business unit, called Evergreen
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.